Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tubal ligation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,506 result(s) found for: Tubal ligation. Displaying page 7 of 126.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2015-004876-31 Sponsor Protocol Number: 204745 Start Date*: 2016-03-28
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, single arm study to investigate the safety, pharmacokinetics and pharmacodynamics of repeat doses of inhaled nemiralisib in patients with APDS/PASLI
    Medical condition: patients with APDS/PASLI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10024970 Respiratory tract infections HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001036-25 Sponsor Protocol Number: UNI91103-201 Start Date*: 2021-06-01
    Sponsor Name:UNION therapeutics A/S
    Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000136-59 Sponsor Protocol Number: KVD824-201 Start Date*: 2021-09-24
    Sponsor Name:Kalvista Pharmaceuticals Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Tre...
    Medical condition: Hereditary Angioedema Type I or II
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004850 10080956 Hereditary angioedema type I LLT
    24.0 100000004850 10080960 Hereditary angioedema type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001243-36 Sponsor Protocol Number: BIA-2093-311/EXT Start Date*: 2015-11-06
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MU...
    Medical condition: Adult patients with recently diagnosed partial-onset seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) LT (Completed) CZ (Completed) LV (Completed) PT (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) EE (Completed) AT (Completed) BG (Completed) SK (Completed) FI (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003453-13 Sponsor Protocol Number: CE01-301 Start Date*: 2014-06-18
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Ad...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) LV (Completed) DE (Completed) ES (Completed) RO (Completed) SK (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2016-001694-32 Sponsor Protocol Number: 9785-CL-0123 Start Date*: 2017-01-17
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
    Medical condition: metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) BE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) LT (Prematurely Ended) SK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing) GR (Completed) AT (Trial now transitioned) NO (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002163-24 Sponsor Protocol Number: M04-690 Start Date*: 2004-11-23
    Sponsor Name:Abbott Laboratories
    Full Title: A Multi-Centre Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Croh...
    Medical condition: Crohn's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) SE (Completed) GB (Completed) ES (Completed) IT (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000775-34 Sponsor Protocol Number: 01-04-TL-475-002 Start Date*: 2004-11-17
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia
    Medical condition: Treatment of patients with primary dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7 10058108 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) CZ (Completed) EE (Completed) SK (Completed) LV (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005185-18 Sponsor Protocol Number: HEPA-CRV431-207 Start Date*: 2022-07-13
    Sponsor Name:Hepion Pharmaceuticals, Inc.
    Full Title: ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVAN...
    Medical condition: NONALCOHOLIC STEATOHEPATITIS AND ADVANCED LIVER FIBROSIS
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004871 10086370 NASH with fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000555-24 Sponsor Protocol Number: 2015-100752 Start Date*: 2016-06-16
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-c...
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing) FR (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000648-25 Sponsor Protocol Number: 165-502 Start Date*: 2019-06-28
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current Management
    Medical condition: Phenylketonuria (PKU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10034873 Phenylketonuria (PKU) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Not Authorised) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004728-11 Sponsor Protocol Number: MR/EUM202 Start Date*: 2005-03-25
    Sponsor Name:Avera Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patien...
    Medical condition: Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002102-57 Sponsor Protocol Number: CICL670A2202 Start Date*: 2006-10-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis
    Medical condition: hereditary hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006678-12 Sponsor Protocol Number: 05ct149fe Start Date*: 2007-06-29
    Sponsor Name:Haupt Pharma Wolfratshausen GmbH
    Full Title: Nasal Transmucosal Fentanyl Citrate (NTFC) versus Oral Morphine Sulphate (OMS): A double-blind, double dummy, randomised, multi-centre, comparative cross-over study for the treatment of breakthroug...
    Medical condition: Cancer-related breakthrough pain
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064556 Breakthrough pain LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003516-62 Sponsor Protocol Number: CYT003-QbG10 08 Start Date*: 2007-10-19
    Sponsor Name:Cytos Biotechnology AG
    Full Title: Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis.
    Medical condition: Adult patients with perennial allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039097 Rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007190-20 Sponsor Protocol Number: D144AC00003 Start Date*: 2009-12-14
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) i...
    Medical condition: Acut mania in subjects with bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001582-25 Sponsor Protocol Number: D7550C00003 Start Date*: 2017-09-29
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 in patients with coronary artery ...
    Medical condition: Coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-011800-44 Sponsor Protocol Number: DIM20 Start Date*: 2009-10-07
    Sponsor Name:Medivation, Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease
    Medical condition: Huntington disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002969-37 Sponsor Protocol Number: RA3103730 Start Date*: 2005-10-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship.
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001558-26 Sponsor Protocol Number: ADG103440 Start Date*: 2005-10-11
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR WEE...
    Medical condition: Dyslipidaemia and overweight
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052066 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 11:22:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA